Balance athletic goals with arrhythmia risk: match the device model and sensor to the sport, and use stress testing to set detection zones and avoid inappropriate therapy.

One initial treatment is a cardioversion, which involves using a defibrillator to deliver an electric shock to the heart to restore rhythm. It’s often successful, but sometimes only temporarily.

[Image courtesy of Biotronik] Biotronik today announced the successful first-in-human implantations of its LivIQ leadless pacemaker system. The implants came in Australia as part of the company’s ...

Sen. John Fetterman was hospitalized Thursday after suffering injuries to his face in a fall due to a serious heart condition, ventricular fibrillation. This life-threatening condition is the ...

Dr. Zhuoshan Huang: A 79-year-old man was admitted to the Third Affiliated Hospital of Sun Yat-sen University in Guangzhou, China, because of dyspnea and edema in the arms and legs. The patient had ...

Acute pulmonary embolism (APE), a critical complication following permanent pacemaker implantation, presents profound therapeutic challenges when occurring during the early postoperative phase. We ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

If you have a racing or irregular heartbeat, also known as an arrhythmia, one likely suspect is atrial fibrillation (AFib). “Of all the possible heart rhythm disorders, atrial fibrillation is by far ...

In an evolution of medical technology that dates to the 1950s, pacemakers that contain no lead components and are less intrusive than earlier versions are on the market. This year marked the ...

Estimates suggest that around three million Americans are living with cardiac pacemakers, according to the American Heart Association. Now, thanks to MountainStar Healthcare, a new kind of pacemaker – ...

The Aveir dual-chamber leadless pacemaker [Image courtesy of Abbott] Abbott (NYSE: ABT) + published findings from the AVEIR DR i2i study evaluating the company’s novel dual-chamber leadless pacemaker ...